Frequency Therapeutics was acquired by or merged with Korro Bio in a strategic corporate transaction executed through an all-stock merger agreement, uniting the publicly listed entities under the Korro Bio corporate identity. Following the successful completion of the business combination, the combined enterprise pivoted its primary operational focus entirely toward advancing Korro's proprietary RNA editing platform and developing novel genetic medicines, while legacy clinical programs and operational structures from the prior entity were systematically integrated or wound down to streamline financial resources and extend the combined corporate cash runway.